Total Valuation
Ceryvyn Therapeutics Limited has a market cap or net worth of €10.01M. The enterprise value is -€18.21.
Market Cap€10.01M
Enterprise Value-€18.21
Share Statistics
Ceryvyn Therapeutics Limited has 170,997,270 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding170,997,270
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Ceryvyn Therapeutics Limited’s return on equity (ROE) is 2.91 and return on invested capital (ROIC) is -147.39%.
Return on Equity (ROE)2.91
Return on Assets (ROA)-1.17
Return on Invested Capital (ROIC)-147.39%
Return on Capital Employed (ROCE)-1.54
Revenue Per Employee3.78K
Profits Per Employee-6.67M
Employee Count33
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Ceryvyn Therapeutics Limited is ―. Ceryvyn Therapeutics Limited’s PEG ratio is -0.00133.
PE Ratio―
PS Ratio1215.83
PB Ratio-2.00
Price to Fair Value-2.00
Price to FCF-0.94
Price to Operating Cash Flow-1.56
PEG Ratio-0.00133
Income Statement
In the last 12 months, Ceryvyn Therapeutics Limited had revenue of 124.67K and earned -220.24M in profits. Earnings per share was -22.16.
Revenue124.67K
Gross Profit21.72K
Operating Income-191.84M
Pretax Income-229.65M
Net Income-220.24M
EBITDA-200.02M
Earnings Per Share (EPS)-22.16
Cash Flow
In the last 12 months, operating cash flow was -243.71M and capital expenditures 0.00, giving a free cash flow of -137.45M billion.
Operating Cash Flow-243.71M
Free Cash Flow-137.45M
Free Cash Flow per Share-0.80
Dividends & Yields
Ceryvyn Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.47
52-Week Price Change-99.20%
50-Day Moving Average2.46
200-Day Moving Average2.87
Relative Strength Index (RSI)100.00
Average Volume (3m)0.00
Important Dates
Ceryvyn Therapeutics Limited upcoming earnings date is Aug 28, 2026, TBA (Confirmed).
Last Earnings DateMar 1, 2026
Next Earnings DateAug 28, 2026
Ex-Dividend Date―
Financial Position
Ceryvyn Therapeutics Limited as a current ratio of 2.94, with Debt / Equity ratio of -186.85%
Current Ratio2.94
Quick Ratio2.94
Debt to Market Cap0.93
Net Debt to EBITDA0.15
Interest Coverage Ratio-6.34
Taxes
In the past 12 months, Ceryvyn Therapeutics Limited has paid -9.41M in taxes.
Income Tax-9.41M
Effective Tax Rate0.04
Enterprise Valuation
Ceryvyn Therapeutics Limited EV to EBITDA ratio is -0.60, with an EV/FCF ratio of -0.75.
EV to Sales968.58
EV to EBITDA-0.60
EV to Free Cash Flow-0.75
EV to Operating Cash Flow-0.75
Balance Sheet
Ceryvyn Therapeutics Limited has €172.47M in cash and marketable securities with €141.65M in debt, giving a net cash position of €30.82M billion.
Cash & Marketable Securities€172.47M
Total Debt€141.65M
Net Cash€30.82M
Net Cash Per Share€0.18
Tangible Book Value Per Share-€0.95
Margins
Gross margin is 100.00%, with operating margin of -153885.37%, and net profit margin of -176665.73%.
Gross Margin100.00%
Operating Margin-153885.37%
Pretax Margin-184215.67%
Net Profit Margin-176665.73%
EBITDA Margin-160443.72%
EBIT Margin-159940.37%
Analyst Forecast
The average price target for Ceryvyn Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―